The Valley Desk

Clinical trial reportMultiple sclerosis and related disordersPublished

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Multiple sclerosis and related disorders
Published
Subject terms
Humans; Multiple Sclerosis, Relapsing-Remitting; Benzylidene Compounds; Thiazoles; Magnetic Resonance Imaging; Treatment Outcome; Double-Blind Method; Adult; Middle Aged; Female; Male; Young Adult
PubMed ID
42561748
Added to directory
Source checked

Report a correction or request removal